Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers.

K A Phillips1

  • 1Peter MacCallum Cancer Institute, Victoria, Australia. PhillipsKelly@petermac.unimelb.edu

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Personality traits and disorders in people with body dysmorphic disorder (BDD): A systematic review.

Journal of psychiatric research·2026
Same author

Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

New Medicare Coverage Policy for Next-Generation Tumor Sequencing: A Key Shift in Coverage Criteria With Broad Implications Beyond Medicare.

JCO precision oncology·2019
Same author

Consumer and clinician perspectives on personalising breast cancer prevention information.

Breast (Edinburgh, Scotland)·2018
Same author

Development and pilot testing of a Decision Aid (DA) for women with early-stage breast cancer considering contralateral prophylactic mastectomy.

Breast (Edinburgh, Scotland)·2018
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Hereditary breast cancers (HBC) show distinct phenotypes linked to BRCA1 or BRCA2 mutations. BRCA1-associated HBC typically presents as high-grade, estrogen receptor-negative tumors, aiding in genetic testing selection.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Breast cancer is a heterogeneous disease with diverse molecular genetic pathways.
  • Hereditary breast cancers (HBC) offer insights into these pathways due to germline mutations in BRCA1 or BRCA2.
  • Understanding these genetic links is crucial for accurate diagnosis and treatment.

Purpose of the Study:

  • To investigate the distinct molecular and clinical phenotypes of hereditary breast cancers.
  • To explore the potential of tumor characteristics in identifying individuals who may benefit from BRCA1/BRCA2 mutation testing.
  • To examine the role of BRCA1 in non-hereditary breast cancer pathogenesis.

Main Methods:

  • Comparative analysis of tumor morphology and clinical characteristics in BRCA1-associated HBC versus BRCA2-associated HBC.

Related Experiment Videos

  • Review of existing literature and studies on hereditary and non-hereditary breast cancer phenotypes.
  • Exploration of gene expression patterns, specifically BRCA1 underexpression in non-HBC.

    • Main Results:

    • BRCA1-associated HBC consistently exhibits a phenotype of high tumor grade and estrogen receptor negativity.
    • Phenotype descriptions for BRCA2-associated HBC are inconsistent across studies.
    • Emerging evidence suggests BRCA1 underexpression in a subset of non-HBC may lead to a similar phenotype as hereditary counterparts.

    Conclusions:

    • The specific phenotype of BRCA1-associated tumors can potentially aid in selecting patients for BRCA1 mutation testing.
    • Further research is needed to validate the utility of this phenotypic approach.
    • BRCA1 may play a role in the pathogenesis of sporadic breast cancers through gene underexpression, mirroring hereditary patterns.